
















Lead Asset in Phase II and 3 Priority Assets Advancing to Clinical Stage in 2022 / 2023

Molecule	Biosion's Right	Modality / Target	Indication	Development Stage				Partner
				Preclinical	IND	Phase I	Phase II	
BSI-045B	Ex China	TSLP	Auto-immune	Global Phase I moving to Phase II in 2022				 
				China Phase II ongoing				
BSI-038	Ex China	CD40	Solid Tumors	Pre-IND				 
				China Phase I ongoing				
BSI-060T	China	Siglec-15	Solid Tumors	China IND in 2022				 
				U.S. IND in 2022				
BSI-585	China	PD1/ILT4	Solid Tumors	China IND in 2022				 
				U.S. IND in 2022				
BSI-04702	China	TROP2 ADC	Solid Tumors	China IND in 2023				 
				Ex-China IND in 2023				
BSI-075	Global	SIRPα	Solid Tumors	Global IND in 2023				
BSI-502	Global	FIC Bispecific	Auto-immune	Global IND in 2023				
BSI-510	Global	FIC Bispecific	Solid Tumors	Global IND in 2023				
BSI-500	Ex China	FIC Bispecific	Solid Tumors	Pre-clinical				
BSI-001	Ex China	HER2-5g9	Solid Tumors	Pre-clinical				
20+ Preclinical	Global	mAb, ADC, Bi-specific approaches	Oncology / Immunology / Auto-Immune	3+ INDs per year				